Nanopharmaceuticals Market Projected to Gain Significant Value by 2025 | Industry Size, Share, Growth and Outlook
Seattle, WA -- (SBWIRE) -- 12/04/2019 -- Nanopharmaceuticals are drugs or a therapeutic delivery system that operates at the nanoscale level. The novel approach can be used for early detection and treatment of various chronic diseases such as cancer. Therefore, increasing prevalence of cancer and adoption of targeted therapies for treatment of the disease is expected to propel growth of the EMEA nanopharmaceuticals market. For instance, according to a study published in the European Journal of Cancer in August 2018, cancer is now the leading cause of premature death (defined as death below the age of 70 years) in 28 of the 40 European countries and is the second most common in the remaining countries.
Nanopharmaceuticals offer site-specific targeting of active agents. This has led several governments to invest in R&D related to targeted therapies, which is also expected to boost growth of the market. For instance, according to the International Cancer Research Partnership for the United Kingdom (UK), France and the Netherlands (for 2014 and 2015), 57% of funding from government and nongovernment organization sectors was assigned to therapy?oriented biology and drug development with 7% to prevention and 13% each to aetiology and to early detection, diagnosis and prognosis. Moreover, in December 2019, Ministry of Science, Research and Technology of Iran unveiled plans for the establishment of four new innovation factories across the country. The Azadi Innovation Factory started in western Tehran under this initiative, includes 10 separate sections and a central building providing opportunities for Iranian start-ups in a broad range of fields, such as tourism, architecture and urban life, nanopharmaceuticals, artificial intelligence, biotechnology, insurance and financial innovations, content creation, and cyber security.
Get Exclusive Sample Copy of "Nanopharmaceuticals" Market Report at https://www.stratagemmarketinsights.com/sample/7184
Increasing R&D in the field of nanopharmaceuticals is expected to boost growth of the EMEA nanopharmaceuticals market. For instance, in September 2019, researchers from the Institute for Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland reported use of ovarian cancer tissues to systematically identify concurrently overexpressed G-protein-coupled-receptors (GPCRs) and kinases. The study is expected to guide the future design of nanoparticles, which will dock to GPCRs on cancer cells via specific ligands and deliver anticancer compounds after receptor mediated internalization. Moreover, in August 2018, researchers from Hungarian Academy of Sciences and University of Pannonia reported development of Doxorubicin and sorafenib co-loaded therapeutic nanocomposites using PLGA- and PEG-PLGA-encapsulating polymers, respectively. The nanoparticles offered potential physical and chemical properties with high yield, high drug encapsulation efficiency, and high drug loading.
- Increasing adoption of targeted therapies for the treatment of chronic diseases is expected to propel growth of the EMEA nanopharmaceuticals market
- Increasing investment in R&D and government initiatives in the field of nanopharmaceuticals is also expected to boost growth of the market
- Major players operating in the EMEA nanopharmaceuticals market include, Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly and Company, Astrazeneca, Johnson & Johnson, Celgene, Novavax, and Stryker
Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Nanopharmaceuticals for these regions, from 2014 to 2025 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.
EMEA Nanopharmaceuticals market competition by top manufacturers/players, with Nanopharmaceuticals sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including; Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy
On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into;
--Solid Lipid Nanoparticles
--Microemulsion And Nanoemulsion
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Nanopharmaceuticals for each application, including;
If you have any special requirements, please let us know and we will offer you the report as per your requirements. Please mention your specific requirements here: https://www.stratagemmarketinsights.com/quiry/7184
Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with an cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide. Our reports cover various end-use industries such as Aerospace and Defense, Agriculture, Food and Beverages, Automotive, Chemicals and Materials, Consumer Goods and Retail, Electronics, Energy, Mining, and Utilities, Pharmaceuticals, Manufacturing and Construction, Services, and Healthcare, and ICT.